Vasorelaxation by red blood cells and impairment in diabetes: reduced nitric oxide and oxygen delivery by glycated hemoglobin.
D000818:Animals; D001013:Aorta, Thoracic; D015687:Cell Hypoxia; D003920:Diabetes Mellitus / Q000097:blood* / Q000503:physiopathology; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism; D004912:Erythrocytes / Q000737:chemistry / Q000502:physiology*; D006442:Glycated Hemoglobin / Q000378:metabolism*; D006031:Glycosylation; D006454:Hemoglobins / Q000378:metabolism*; D008297:Male; D008833:Microcirculation; D009569:Nitric Oxide / Q000097:blood*; D010100:Oxygen / Q000097:blood*; D010656:Phenylephrine / Q000494:pharmacology; D011817:Rabbits; D014226:Triazenes / Q000494:pharmacology; D014662:Vasoconstrictor Agents / Q000494:pharmacology; D014664:Vasodilation / Q000502:physiology*; D019323:omega-N-Methylarginine / Q000494:pharmacology
D006442:Glycated Hemoglobin; D006454:Hemoglobins; D009569:Nitric Oxide; D010100:Oxygen; D010656:Phenylephrine; D014226:Triazenes; D014662:Vasoconstrictor Agents; D019323:omega-N-Methylarginine; C103574:S-nitrosohemoglobin; C008657:nitrosyl hemoglobin; C099612:NOC 9